SPDL1 and neoplasm: In other words, PD1–sPDL2 binding could compete with PD1–sPDL1 binding and lead to decreased sPDL1-mediated T-cell cytotoxicity against the tumor, as we observed in our study on the deteriorated survival of OS patients with high levels of sPDL2.